Erlocip 100 Tablet contains Erlotinib 100 mg, a potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Erlotinib functions by selectively inhibiting the intracellular phosphorylation of EGFR, thereby blocking downstream signaling pathways involved in tumor cell proliferation, survival, and metastasis. It is indicated for patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen, as well as in combination with gemcitabine for locally advanced, unresectable, or metastatic pancreatic cancer. Erlocip 100 is administered orally, with dosing individualized based on patient tolerance and clinical response. Common adverse effects include rash, diarrhea, anorexia, and fatigue, which are generally manageable with supportive care. Serious adverse reactions may include interstitial lung disease and hepatotoxicity, necessitating close monitoring during therapy. Erlotinib’s metabolism primarily involves the cytochrome P450 system, particularly CYP3A4, and caution is advised when co-administered with strong inducers or inhibitors of this enzyme. Patients should be counseled on adherence, potential side effects, and the importance of regular follow-up for optimal therapeutic outcomes. Erlocip 100 Tablet offers a targeted therapeutic approach, contributing significantly to the management of specific malignancies.